ClinicalTrials.gg
RecruitingNCT07326111PERIODSUpdated Jan 8, 2026

A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese

A Phase 4 interventional study of Tirzepatide as an adjunct to lifestyle intervention and Placebo as an adjunct to lifestyle intervention in Polycystic Ovary Syndrome (PCOS) and Obesity & Overweight, sponsored by University of Bonn. Recruiting at 2 sites in Germany. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by University of Bonn · Phase 4, Interventional, and Treatment

How we know · 2 judgments

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This clinical study examines whether tirzepatide can improve ovarian dysfunction in premenopausal women with polycystic ovary syndrome (PCOS) who are overweight or have obesity. Tirzepatide is already approved for the treatment of diabetes and obesity, but its effects on ovarian dysfunction in PCOS are not yet known. Participants will be randomly assigned to tirzepatide or placebo in a double-blinded manner.

The goal of the study is to demonstrate that tirzepatide, at the maximum tolerated dose, is superior to placebo for improvement of ovarian dysfunction as defined by menstrual irregularity in overweight or obesity-related PCOS.

All participants will have a screening visit, followed by 72 weeks of treatment. Treatment includes a 20-week dose-escalation period and a 52-week maintenance period. Lower doses may be used if side effects occur, and the highest tolerated dose will be continued through the maintenance phase. A 4-week safety follow-up will take place after treatment, and long-term follow-up will continue for one year. The study will take place at five clinical trial sites in Germany.

Read the detailed description

PERIODS is a prospective, phase IV, multi-centre, randomized, double-blind and placebo-controlled clinical trial that will investigate the effects of tirzepatide compared with placebo on ovarian dysfunction in premeno-pausal, overweight (BMI ≥ 27 kg/m2) women with PCOS. The primary endpoint is the improvement of ovarian dysfunction as defined by menstrual irregularity and ovulation frequency in overweight or obesity-related PCOS.

All subjects will undergo a screening visit and a 72-week treatment period including a 20-week dose escalation up to the maximum tolerated dose. Lower doses of tirzepatide are permitted if intolerable side effects occur. However, even if a lower dose of tirzepatide turns out to be the maximum tolerated dose, this lower dose will be administered for the entire 20-week dose escalation period, followed by the 52-week maintenance dose.

The safety follow-up period will be 4 weeks (for subjects completing or discontinuing IMP during the first 72 weeks). Long-term follow-up will be one year after discontinuation of IMP.

The trial design is multi-centred with a planned number of 5 participating trial sites in Germany.

02

Conditions studied

  • Polycystic Ovary Syndrome (PCOS)
  • Obesity & Overweight

Keywords

  • pcos
  • tirzepatide
  • obesity
  • reproductive health
  • polycystic ovary syndrome
03

In context

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

This study's planned enrollment of 198 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.

Browse Polycystic Ovary Syndrome studies →

Lead sponsor

University of Bonn is the lead sponsor of 39 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria

  • Written to participate in this clinical trial in accordance with local regulations and the ethical review board governing this clinical trial
  • Subjects

    • motivated, capable, and willing to self-inject IMP, as required for this protocol.
    • motivated, capable, and willing to follow trial procedures for the duration of the clinical trial, includ-ing, but not limited to lifestyle, dietary and exercise advice.
    • motivated, capable, and willing to complete trial diaries and required questionnaires.

Indication-specific Inclusion Criteria

  • Females aged 18 - 45 years of
  • At least 3 years post-menarche and premenopausal
  • ≥ 27 kg/m²
  • Previous diagnosis of PCOS, defined by Rotterdam criteria
  • Oligomenorrhea or secondary amenorrhea with irregular periods (defined as cycle length less than 21 or more than 35 days or \< 8 cycles per year); within the last 10 years (if currently receiving hormonal treatment) OR over the last year in the absence of hormonal contraceptive treatment
  • Biochemical signs of hyperandrogenism with total testosterone in upper 95th Percentile AND free androgen index (FAI) > and/or clinical signs of hyperandrogenism
  • Hormonal contraceptive naïve or not on hormonal contraceptives six months prior to screening, willing to be without hormonal contraceptives for the duration of the clinical trial and to perform safe alternate contraception (barrier methods) during the 72-week IMP intake period and 30 days after the last dose of IMP

General Exclusion Criteria

  • Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial
  • Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the trial results, or may interfere with the subject's participation in this clinical trial

    • Note: Patients with depression or other psychiatric disorder whose disease state is considered stable and expected to remain stable throughout the course of the clinical trial, in the opinion of the investigator, may be considered for inclusion.
    • Note: Subjects with a lifetime suicidal event cannot be considered for inclusion
  • Simultaneous participation in another clinical trial, or participation in a clinical trial taking an investiga-tional product, up to 30 days after last IMP intake in that clinical trial
  • Known or persistent abuse of medication, drugs or alcohol
  • History of an active or untreated or being in remission from a malig-nancy for less than 5 years

    o Excluding basal- or squamous-cell skin cancer or in situ carcinomas of the cervix

  • Prior diagnosis of severe renal impairment or measured as estimated (eGFR) \< 30 mL/min/1.73 m² during screening
  • Acute or chronic hepatitis, signs and symptoms of any other liver disease other than non-alcoholic fatty liver disease, or (ALT) level > 3.0 X the upper limit of normal, as deter-mined by the laboratory during screening
  • History of gastric emptying abnormality (e.g., gastroparesis, gastric outlet obstruction or chronic de-pendence on drugs that significantly affect gastric emptying)
  • Current (positive pregnancy test, e.g., ß-HCG test in urine / serum) or planned pregnancy during the 72-week treatment period from randomization, or nursing women

Indication-specific Exclusion Criteria

  • Prior diagnosis of diabetes mellitus other forms than type 2

    o Note: Excluding prior history of gestational diabetes

  • In case of diabetes mellitus type 2, exclusion of subjects

    • on DPP-4 inhibitors, GLP-1R agonist and/or a dual/triple incretin agonist (up to 6 months prior to screening)
    • on sulfonylureas or insulin (basal and/or bolus)
    • with uncontrolled diabetes ( > 8.5%)
    • with non-proliferative diabetic retinopathy requiring acute treatment
    • with diabetic maculopathy
    • Note: use of metformin or SGLT-2-inhibitor (if needed for glycemic control in type-2-diabetes) is allowed
  • Current or prior treatment (up to 6 months prior to screening) with GLP-1R agonist or a dual incretin agonist for obesity or other indications
  • Use of inositol formulations (up to 6 months prior to screening)
  • Congenital adrenal hyperplasia (CAH, classic and non-classic forms)
  • Thyroid, pituitary, and/or adrenal disease (if not appropriately treated)

    o Note: Excluding stable disease and/or stable drug dose 12 weeks before screening

  • Hyperprolactinaemia
  • Known history of benign intrauterine lesions
  • Hysterectomy
  • Known history of against tirzepatide or
  • Known history of hypersensitivity against medroxyprogesterone acetate or dydrogesterone or any other ingredients of the Auxiliary Medicinal Products
  • Known personal or family history of medullary thyroid cancer or subjects with Multiple Endocrine Ne-oplasia syndrome type 2 (MEN 2)
  • Elevated calcitonin levels as determined by the laboratory during screening

    • ≥ 20 ng/L, if eGFR ≥ 60 mL/min/1.73 m2
    • ≥ 35 ng/L, if eGFR \< 60 mL/min/1.73 m2
  • Known secondary cause of obesity (i.e., Cushing syndrome) or monogenetic or syndromic forms of obesity (i.e., melanocortin 4 receptor deficiency or Prader Willi Syndrome)
  • Known history of acute or chronic pancreatitis
  • Previous or planned bariatric surgery or endoscopic and/or device-based therapy for obesity

    o Note: excluding liposuction or abdominoplasty if performed > 1 year prior to screening

  • Vaginal bleeding of unknown cause
  • Known thromboembolic events or active thrombophlebitis
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
198 participants (estimated)

Study arms

  • Active comparator
    Treatment Group

    Weekly abdominal subcutaneous injection of tirzepatide over a 72-week treatment period including a 20-week dose-escalating regiment and 52-week treatment period adjunct to reduced-calorie diet and increased physical activity

    Drug: Tirzepatide as an adjunct to lifestyle intervention

  • Placebo comparator
    Control Group

    Weekly abdominal subcutaneous injection of a placebo injectable over a 72-week period ad-junct to reduced-calorie diet and increased physical activity.

    Drug: Placebo as an adjunct to lifestyle intervention

Interventions

  • DrugTirzepatide as an adjunct to lifestyle intervention

    Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg Mode of application: weekly subcutaneous injection, prefilled pen injector Duration of treatment: 72 weeks (20 weeks dose escalation, 52 weeks treatment with maximum tolerated dose)

  • DrugPlacebo as an adjunct to lifestyle intervention

    Dose: Placebo Pens to mimic doses 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg Mode of Application: weekly subcutaneous injection, prefilled pen injector Duration of Treatment: 72 weeks

This study also gives TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Improvement of ovarian dysfunction as defined by menstrual irregularity in overweight or obesity-related PCOS

    1. Mean menstrual bleeding ratio (number of menstrual bleedings divided by treatment period in months) during the last 52 weeks of treatment, assessed at 72 weeks after randomization 2. Mean change in menstrual bleeding ratio from baseline, calculated at 72 weeks after randomization (with baseline defined as mean menstrual bleeding ratio during the 6 months before randomization)

    Time frame: At 72 weeks after randomization

  2. Key Secondary - Improvement of ovarian dysfunction as defined by ovulation frequency in overweight or obesity-related PCOS

    Total number of biochemically confirmed ovulatory events (within 24 weeks after completed dose titration) measured by weekly serum progesterone

    Time frame: Within 24 weeks after completed dose titration

Secondary outcomes

  1. Percentage of Participants With Normalization of Menstrual Cycle

    Normalization of the menstrual cycle is defined as a cycle length greater than 21 days and less than 35 days, or more than 8 cycles per year. This endpoint compares the proportion of subjects achieving this criteria in the tirzepatide group versus the placebo group.

    Time frame: Week 72

  2. Change From Baseline in Serum Anti-Müllerian Hormone (AMH)

    Assessment of AMH as a surrogate marker for ovarian follicle pool and ovarian morphology.

    Time frame: Baseline and Week 72

  3. Change From Baseline in Biochemical Androgen Profile

    Evaluation of the androgenic status including Total Testosterone, Sex Hormone-Binding Globulin (SHBG), DHEA-S, and Androstenedione. Results will be reported as the change from baseline or the ratio of Week 72 to baseline.

    Time frame: Baseline and Week 72

  4. Change From Baseline in Calculated Free Androgen Index (FAI) and Calculated Free Testosterone

    FAI is calculated as (Total Testosterone/SHBG) x 100. Free Testosterone is calculated using the Vermeulen formula or a similar validated method based on Total Testosterone and SHBG levels.

    Time frame: Baseline and Week 72

  5. Change From Baseline in Pituitary-Gonadal Hormones (LH, FSH, Estradiol, Progesterone)

    Assessment of the hormonal regulation of the ovarian cycle by measuring Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), Estradiol, and Progesterone.

    Time frame: Baseline and Week 72

  6. Percentage Change in Body Weight from Baseline to Week 72

    Relative change in total body weight compared to the starting weight.

    Time frame: Baseline and Week 72

  7. Percentage of Participants Achieving ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% Body Weight Loss

    Proportion of subjects in each treatment arm who reach the specified weight loss thresholds at Week 72.

    Time frame: Baseline and Week 72

  8. Change from Baseline in Body Composition (BIA) at Week 72

    Mean change in fat mass and fat-free mass as measured by Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseline and Week 72

  9. Change from Baseline in Waist Circumference and Waist-to-Hip Ratio

    Measurement of abdominal fat distribution change from randomization to Week 72.

    Time frame: Baseline and Week 72

  10. Change from Baseline in Fasting Glucose and HbA1c at Week 72

    Assessment of long-term and fasting glycemic control.

    Time frame: Baseline and Week 72

  11. Change from Baseline in Systemic Insulin Sensitivity Indices

    Evaluation of insulin sensitivity using the Quantitative Insulin Sensitivity Check Index (QUICKI), Homeostasis Model Assessment (HOMA-IR), and Matsuda's Insulin-Sensitivity Index derived from OGTT data.

    Time frame: Baseline and Week 72

  12. Change from Baseline in Fasting Lipid Profile at Week 72

    Mean change in Triglycerides and the Triglyceride-to-HDL Ratio.

    Time frame: Baseline and Week 72

  13. Change from Baseline in Fasting Lipid Profile at Week 72

    Mean change in Total Cholesterol, LDL Cholesterol and HDL cholesterol

    Time frame: Baseline and Week 72

  14. Change from Baseline in Liver Enzymes and Non-invasive Biomarkers (FLI, FIB-4)

    Assessment of liver health via Fatty Liver Index (FLI) and FIB-4 Score.

    Time frame: Baseline and Week 72

  15. Change from Baseline in Liver Stiffness and Fat Content at Week 72

    Measurement of hepatic steatosis and fibrosis via imaging (e.g., Transient Elastography/FibroScan).

    Time frame: Baseline and Week 72

  16. Change from Baseline in Systolic and Diastolic Blood Pressure

    Mean change in SBP and DBP from randomization to Week 72.

    Time frame: Baseline and Week 72

  17. Change from Baseline in High-Sensitivity C-Reactive Protein (hs-CRP)

    Marker for systemic meta-inflammation.

    Time frame: Baseline and Week 72

  18. Change From Baseline in the 36-Item Short Form Survey (SF-36) at Week 72

    The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores. Each scale is transformed to a 0-100 range, where 0 indicates the lowest level of health and 100 indicates the highest level of health (higher scores mean a better outcome).

    Time frame: Baseline and Week 72

  19. Change From Baseline in the Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ)

    The PCOSQ measures health-related quality of life in women with PCOS across five domains (Emotions, Body Hair, Weight, Infertility, and Menstrual Problems). Each item is scored on a 7-point scale. Domain scores range from 1 to 7, where higher scores indicate better health-related quality of life/less distress.

    Time frame: Baseline and Week 72

  20. Change From Baseline in the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)

    The EQ-5D-5L consists of a descriptive system (5 dimensions) and a Visual Analogue Scale (VAS). The VAS records the respondent's self-rated health on a vertical scale where the endpoints are labeled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). Higher scores mean a better outcome.

    Time frame: Baseline and Week 72

  21. Patient Global Impression of Severity (PGI-S) at Week 72

    The PGI-S is a single-item question asking the patient to rate the severity of their condition. It uses a 5-point scale: 1 (None), 2 (Mild), 3 (Moderate), 4 (Severe), 5 (Very Severe). A decrease in score indicates an improvement in condition.

    Time frame: Baseline and Week 72

Other outcomes

  1. Dose-Dependent Menstrual Bleeding Ratio at Week 72

    Evaluation of the dose-response relationship of tirzepatide (5 mg, 10 mg, and 15 mg) compared to placebo. Mean menstrual bleeding ratio at 72 weeks after randomization.

    Time frame: Week 72

  2. Dose-Dependent Change in Mean Menstrual Bleeding Ratio at Week 72

    Evaluation of the dose-response relationship of tirzepatide (5 mg, 10 mg, and 15 mg) compared to placebo. Mean change in menstrual bleeding ratio at 72 weeks after randomization

    Time frame: Baseline and Week 72

  3. Dose-Dependent Normalization of Menstrual Cycle

    Evaluation of the dose-response relationship (5 mg, 10 mg, and 15 mg) compared to placebo. Percentage of subjects achieving a cycle length \> 21 and \< 35 days or \> 8 cycles/year.

    Time frame: 72 weeks

  4. Total Number of Biochemically Confirmed Ovulatory Events (Dose-Response)

    Evaluation of the dose-response relationship (5 mg, 10 mg, and 15 mg) compared to placebo. Number of ovulatory events (serum progesterone ≥ 3 ng/mL) during the 24 weeks following completed dose titration.

    Time frame: 24 weeks following completed dose titration

  5. Change From Baseline in Ovarian Volume (MTD vs. Placebo)

    Change in ovarian volume (OV) measured by transvaginal ultrasound, comparing the maximum tolerated dose (MTD) of tirzepatide to placebo.

    Time frame: 72 weeks

  6. Change From Baseline in Follicle Number Per Ovary (MTD vs. Placebo)

    Change in follicle number per ovary (FNPO) measured by transvaginal ultrasound (MTD vs. placebo).

    Time frame: 72 weeks

  7. Change From Baseline in Hirsutism (Ferriman-Gallwey Score) at MTD

    Assessment of hair growth using the modified Ferriman-Gallwey score. Scale: 0 (no hair) to 36 (severe hirsutism). A decrease in score indicates improvement.

    Time frame: 72 weeks

  8. Change From Baseline in Female Pattern Baldness (Ludwig Scale) at MTD

    Assessment using the Ludwig scale (Grade I, II, or III). Higher grades indicate more severe hair loss. A decrease in grade indicates improvement.

    Time frame: 72 weeks

  9. Change From Baseline in Acne Lesion Count at MTD

    Count of acne spots per side of the face (MTD vs. placebo).

    Time frame: 72 weeks

  10. Percentage of Participants Reaching HbA1c Targets (< 7% and < 6.5%) at MTD

    Proportion of diabetic participants reaching glycemic targets (MTD vs. placebo).

    Time frame: 72 weeks

  11. Change From Baseline in HbA1c at MTD

    Mean change in HbA1c (%) from randomization to Week 72 (MTD vs. placebo).

    Time frame: 72 weeks

  12. Menstrual Bleeding Ratio Within 52 Weeks After Drug Discontinuation

    Mean bleeding ratio calculated during the off-drug period (Week 72 to Week 124).

    Time frame: Week 124

  13. Change in Menstrual Bleeding Ratio (Treatment vs. Follow-up)

    Comparison of the bleeding ratio during the treatment phase (up to Week 72) versus the bleeding ratio during the 52-week follow-up phase (Week 124).

    Time frame: Week 72 to Week 124

  14. Percentage of Participants Maintaining Menstrual Cycle Normalization at Week 124

    Proportion of participants who still meet the criteria for normal cycles (21-35 days or \>8/year) 52 weeks after stopping tirzepatide.

    Time frame: Week 124

  15. Change From Baseline in Ovarian Volume (OV) and Follicle Number (FNPO) at Week 124

    Assessment of sustained effects on ovarian morphology via transvaginal ultrasound 52 weeks after drug discontinuation.

    Time frame: Baseline and Week 124

  16. Change From Baseline in Serum Anti-Müllerian Hormone (AMH) at Week 124

    Evaluation of AMH levels as a marker of ovarian reserve and morphology after the 52-week follow-up period.

    Time frame: Baseline and Week 124

  17. Change From Baseline in Androgen Profile and Gonadotropins at Week 124

    Includes Total Testosterone, Estradiol, Progesterone, SHBG, DHEA-S, Androstenedione, LH, and FSH measured 52 weeks after drug discontinuation.

    Time frame: Baseline and Week 124

  18. Change From Baseline in Calculated Free Androgen Index (FAI) and Free Testosterone at Week 124

    Calculation of FAI \[(Total Testosterone/SHBG) x 100\] and free testosterone to assess sustained biochemical improvement after drug discontinuation.

    Time frame: Baseline and Week 124

  19. Sustained Improvement in Hirsutism (Ferriman-Gallwey Score) at Week 124

    mFG score (range 0-36, higher score = more severe) measured 52 weeks after drug discontinuation. A lower score compared to baseline indicates sustained improvement.

    Time frame: Baseline and Week 124

  20. Sustained Improvement in Female Pattern Baldness (Ludwig Scale) and Acne at Week 124

    Assessment of hair loss (Ludwig Grade I-III) and acne lesion counts (number of spots) at the end of the follow-up period.

    Time frame: Baseline and Week 124

  21. Clinical Pregnancy Rate at Week 124

    Percentage of subjects who achieve clinical pregnancy (confirmed by ultrasound visualization of fetal cardiac activity) after drug discontinuation. This includes conception via natural/spontaneous means, pharmacologically induced ovulation (e.g., letrozole, clomiphene), or Assisted Reproductive Technology (ART).

    Time frame: From Week 72 to Week 124

  22. Change From Baseline in Body Weight and Composition at Week 124

    Mean and percentage change in body weight, fat mass, and fat-free mass (measured by BIA) 52 weeks after drug discontinuation.

    Time frame: Baseline and Week 124

  23. Percentage of Participants Maintaining Weight Loss Thresholds at Week 124

    Proportion of participants maintaining ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% weight loss from randomization at the end of the follow-up period.

    Time frame: Week 124

  24. Change From Baseline in Waist Circumference and Waist-to-Hip Ratio at Week 124

    Assessment of abdominal fat distribution 52 weeks after drug discontinuation.

    Time frame: Baseline and Week 124

  25. Change From Baseline in Fasting Glucose and HbA1c at Week 124

    Change From Baseline in Fasting Glucose and HbA1c at Week 124

    Time frame: Baseline and Week 124

  26. Change From Baseline in Insulin Sensitivity Indices (QUICKI, HOMA-IR, Matsuda) at Week 124

    Derived from fasting and OGTT data to assess sustained effects on insulin sensitivity.

    Time frame: Baseline and Week 124

  27. Change From Baseline in Fasting Lipid Parameters at Week 124

    Assessment of sustained effects on total cholesterol, HDL and LDL cholesterol 52 weeks after drug discontinuation.

    Time frame: Baseline and Week 124

  28. Change From Baseline in Fasting Lipid Parameters at Week 124

    Assessment of sustained effects and Change From Baseline in fasting triglycerides and Triglyceride-to-HDL Cholesterol Ratio 52 weeks after drug discontinuation.

    Time frame: Baseline and Week 124

  29. Change From Baseline in Liver Enzymes at Week 124

    Mean change in serum levels of liver enzymes (e.g., ALT, AST, GGT) to assess sustained hepatic safety and function 52 weeks after drug discontinuation.

    Time frame: Baseline and Week 124

  30. Change From Baseline in Non-invasive Liver Scores (FLI and FIB-4) at Week 124

    Evaluation of the Fatty Liver Index (FLI) and the Fibrosis-4 (FIB-4) score 52 weeks after drug discontinuation.

    Time frame: Baseline and Week 124

  31. Change From Baseline in Blood Pressure

    Assessment of sustained effects on systolic/diastolic BP

    Time frame: Baseline and 124 weeks

  32. Change From Baseline in hs-CRP at Week 124

    Assessment of sustained effects on systemic meta-inflammation (hs-CRP).

    Time frame: Baseline and week 124

  33. Change From Baseline in the 36-Item Short Form Survey (SF-36) at Week 124

    The SF-36 is a health survey yielding scores from 0 to 100. Higher scores indicate a better health-related quality of life. Assessment of sustained well-being 52 weeks after drug discontinuation.

    Time frame: Baseline and Week 124

  34. Change From Baseline in the PCOS Health-Related Quality of Life Questionnaire (PCOSQ) at Week 124

    The PCOSQ measures five domains (Emotions, Body Hair, Weight, Infertility, Menstrual Problems) on a scale of 1 to 7. Higher scores indicate better health-related quality of life.

    Time frame: Baseline and Week 124

  35. Change From Baseline in EQ-5D-5L Health State Index Score at Week 124

    The EQ-5D-5L Index Score is derived from 5 dimensions (Mobility, Self-care, Usual activities, Pain/discomfort, and Anxiety/depression). Each dimension has 5 levels. The scores are converted into a single index value using a country-specific value set (e.g., German Value Set). The index score ranges from less than 0 (where 0 is death) to 1 (perfect health). Higher scores indicate a better health state.

    Time frame: Baseline and Week 124

  36. Patient Global Impression of Severity (PGI-S) at Week 124

    A single-item scale where patients rate their disease severity from 1 (None) to 5 (Very Severe). A decrease in score indicates improvement.

    Time frame: Week 124

07

Study locations

2 of 2 sites recruiting
  • University Hospital BG Bergmannsheil Bochum General internal medicine, endocrinology and diabetology, gastroenterology and hepatology
    Bochum, 44789, Germany
    Enrolling by invitation
  • University Hospital Bonn Division of Endocrinology, Diabetes and Metabolism
    Bonn, 53127, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual subject data will be available. Individual subject data (including data dictionaries) that underlie results concerning primary or secondary endpoints reported in a published scientific article will be shared on demand after deidentification. Furthermore, the following documents will be made available at least: Trial Protocol and Informed Consent Form. The data will be shared immediately following publication and ending 10 years following publication. Data are made available to researchers after a methodologically sound scientific proposal has been submitted to the Coordinating Investigator, and a steering committee consisting of the Coordinating Investigator, the representative of the Coordinating Investigator, and an authorized SZB member has approved the proposal. The data will be shared to achieve aims in the approved proposal. Proposals should be directed to Wiebke.Fenske@rub.de. To gain access, data requestors will need to sign a data access agreement.

Time frame: The data will be shared immediately following publication and ending 10 years following publication.

Access criteria: To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 41 non-industry phase 4 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 45. This study's planned 36 months is above that.

Counting every sponsor, half of 42 studies reached it within 25 months; a quarter within 11 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 8, 2026
StartActual
Dec 9, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07326111
Lead sponsor
University of Bonn
Collaborators
Heart and Diabetes Center North Rhine-Westphalia, University Hospital, Essen, Ruhr University of Bochum, LMU Klinikum
Responsible party
Charlotte Fries (Senior Physician, University Hospital, Bonn) — Principal investigator
First posted
Jan 8, 2026
Start date
Dec 9, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jan 8, 2026

Study contacts

Wiebke Fenske K. Head of Department at BG Universitätsklinikum Bochum, Professor
Contact
wiebke.fenske@bergmannsheil.de
+49 234 302 3613
Charlotte Fries M. Senior Physician, MD
Contact
charlotte.fries@ukbonn.de
+49 228 287 52533
Wiebke K. Fenske, Professor
principal investigator · BG UniversitätsklinikumBergmannsheil Bochum

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion